# A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin

Study · id `cardio:ct-nct04233801` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04233801](<https://clinicaltrials.gov/study/NCT04233801>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04233801

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 219 participants.

## Technical summary

Registry record NCT04233801. Randomized; triple masking; primary purpose treatment. Start 2020-04-15 (actual); primary completion 2022-03-03 (actual). Results posted on 2023-12-15.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 219 participants (enrolled count; ClinicalTrials.gov record NCT04233801, source copy `cardio:ctgov-nct04233801-2023-12-15`, retrieved 2026-10-26)
- Started: 2020-04-15 (actual) (ClinicalTrials.gov record NCT04233801, source copy `cardio:ctgov-nct04233801-2023-12-15`, retrieved 2026-10-26)
- Primary completion: 2022-03-03 (actual) (ClinicalTrials.gov record NCT04233801, source copy `cardio:ctgov-nct04233801-2023-12-15`, retrieved 2026-10-26)
- Completion: 2022-03-10 (actual) (ClinicalTrials.gov record NCT04233801, source copy `cardio:ctgov-nct04233801-2023-12-15`, retrieved 2026-10-26)
- Results first posted: 2023-12-15 (ClinicalTrials.gov record NCT04233801, source copy `cardio:ctgov-nct04233801-2023-12-15`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04233801, source copy `cardio:ctgov-nct04233801-2023-12-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04233801-2023-12-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Empagliflozin
- Intervention (Drug): Placebo
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

## Provenance

Content hash: a2e7aa18d77fc9636b99f1ce0d314e8133c2858d228096fccc6e6febe79627df
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
